Follistatin Side Effects: Myostatin Inhibitor in Research, Not in the Clinic
Follistatin is a naturally occurring glycoprotein that binds and neutralises members of the TGF-beta superfamily, most notably myostatin. It has been studied in animal models for muscle growth and in early-phase trials for muscular dystrophy gene therapy. It is not FDA-approved as a standalone therapeutic. Compounded peptides marketed as follistatin or follistatin-derived sequences (FST-344, FST-315) are not regulator-supported.
Follistatin is not FDA-approved and lacks controlled human safety data. Not FDA-approved as a standalone product. Investigated in academic and biotech settings for muscular dystrophy gene therapy. Compounded peptide versions are not regulator-supported. This page summarises the published literature and regulator positions. It is not medical advice.
Key Takeaways
- Follistatin is a myostatin inhibitor studied in research and very early-phase trials. Not an approved therapeutic.
- Compounded peptides marketed as follistatin or follistatin-derived sequences are not pharmaceutical-grade.
- WADA prohibits use in competitive sport.
- TGF-beta family modulation has theoretical implications for cardiovascular function, immune regulation, and fibrosis, which is why translation has been slow.
What is Follistatin, and what is it marketed for?
Follistatin (FST). Follistatin binds myostatin and other TGF-beta-family ligands, blocking their inhibition of muscle growth. Animal models with high follistatin expression show large gains in muscle mass. Translation to human therapeutics has progressed slowly because of the complexity of safely modulating TGF-beta signalling.
What side effects and safety concerns have been reported?
The summary below draws from the published literature and regulator statements. Severity classification follows the source documents.
| Concern | What has been reported | Source |
|---|---|---|
| TGF-beta family modulation | Broad effects on cell growth, immune function, and fibrosis if signalling is disrupted | Theoretical concern with sustained high doses |
| Cardiovascular effects | Cardiac and vascular tissues depend on TGF-beta signalling | Theoretical concern with sustained suppression |
| Gray-market product | Compounded peptides marketed as 'follistatin' may be derived peptides of uncharacterised composition | Pharmaceutical-grade follistatin does not exist outside biotech research |
| WADA prohibited | Use in competitive sport is prohibited | Section S2 anabolic agents |
| Long-term safety | Not characterised in any controlled human dataset | All translation efforts have been very early-stage |
Taking Follistatin alongside prescription medicines?
Allmeds scans interactions across your full medication list. Free for individuals.
Common Questions About Follistatin
No. Follistatin is not FDA-approved as a standalone therapeutic. Gene therapy approaches that deliver follistatin sequences have been studied for muscular dystrophy in early-phase trials, but those are distinct from compounded peptide products marketed online.
Follistatin binds myostatin and other TGF-beta-family ligands. By neutralising myostatin, it removes a brake on muscle growth in animal models. The translation of this mechanism to safe human therapeutics has progressed slowly.
Yes. WADA prohibits use of follistatin or follistatin-mimicking agents in competitive sport.
Pharmaceutical-grade follistatin is not available outside biotech research. Compounded peptides sold under the follistatin label are of uncharacterised composition and have no regulator-reviewed safety data.
References
- Lee SJ. Quadrupling muscle mass in mice by targeting TGF-ß signaling pathways. PLoS One. 2007;2:e789. Source.
- Mendell JR et al. A phase 1/2a follistatin gene therapy trial for Becker muscular dystrophy. Mol Ther. 2015. Source.
- World Anti-Doping Agency. WADA Prohibited List. Source.
- U.S. Food & Drug Administration. FDA position on bulk drug substances for compounding. Source.